Cure My Disease

Don't miss your cure!

 Log in / Sign up

Head-to-Head trial tests new shot for rare, debilitating blood vessel disease

NCT ID NCT04157348

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study compares two injectable medications, benralizumab and mepolizumab, for treating a rare autoimmune disease called EGPA. It involves 140 adults whose EGPA keeps coming back or hasn't responded well to standard steroid treatments. The main goal is to see which drug is better at helping patients achieve and maintain remission while reducing their need for steroids.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOUS VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Denver, Colorado, 80206, United States

  • Research Site

    Ann Arbor, Michigan, 48109, United States

  • Research Site

    Rochester, Minnesota, 55905-0001, United States

  • Research Site

    Albuquerque, New Mexico, 87106, United States

  • Research Site

    Great Neck, New York, 11021, United States

  • Research Site

    New York, New York, 10021, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Denison, Texas, 75020, United States

  • Research Site

    Seattle, Washington, 98115, United States

  • Research Site

    Brussels, 1070, Belgium

  • Research Site

    Brussels, 1090, Belgium

  • Research Site

    Calgary, Alberta, T2N 4Z6, Canada

  • Research Site

    Hamilton, Ontario, L8N 4A6, Canada

  • Research Site

    Toronto, Ontario, M5G 1E2, Canada

  • Research Site

    Toronto, Ontario, M5T 3A9, Canada

  • Research Site

    Dijon, 21079, France

  • Research Site

    Marseille, 13915, France

  • Research Site

    Montpellier, 34090, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Paris, 75014, France

  • Research Site

    Paris, 75877, France

  • Research Site

    Suresnes, 92151, France

  • Research Site

    Toulouse, 31059, France

  • Research Site

    Bamberg, 96049, Germany

  • Research Site

    Freiburg im Breisgau, 79106, Germany

  • Research Site

    Hamburg, 20251, Germany

  • Research Site

    Kirchheim, 73230, Germany

  • Research Site

    Lübeck, 23538, Germany

  • Research Site

    Ashkelon, 7830604, Israel

  • Research Site

    Beersheba, 84101, Israel

  • Research Site

    Jerusalem, 91120, Israel

  • Research Site

    Ramat Gan, 52621, Israel

  • Research Site

    Rehovot, 7661041, Israel

  • Research Site

    Tel Aviv, 6423906, Israel

  • Research Site

    Cuneo, 12100, Italy

  • Research Site

    Florence, 50141, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Milan, 20162, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Torino, 10128, Italy

  • Research Site

    Chiba, 260-0877, Japan

  • Research Site

    Kita-gun, 761-0793, Japan

  • Research Site

    Sagamihara-shi, 228-0815, Japan

  • Research Site

    Sendai, 980-8574, Japan

  • Research Site

    Shinjuku-ku, 162-8666, Japan

  • Research Site

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    Leicester, LE3 9QP, United Kingdom

  • Research Site

    London, SE19RT, United Kingdom

  • Research Site

    Portsmouth, PO6 3LY, United Kingdom

Conditions

Explore the condition pages connected to this study.

EOSINOPHILIC GRANULOMATOUS VASCULITIS